There are new features available.
View now.

Search

Type a keyword to start your search

Search for ''

news

Go to news search

Deals

Go to Deals search

Issuers

Go to Issuers search

Destinations

Go to Destinations search

IFR Extra
IFR Extra
IFR Featured
IFR Featured
SIGN IN
REQUEST A TRIAL
My IFR
My Account
My Account
Log Out

Home
People & Markets
People & Markets
Bonds
Bonds
- Global
  Bonds
  / Global
- Americas
  Bonds
  / Americas
  - Corporate
    Bonds
    / Americas
    / Corporate
    Investment Grade
    High Yield
  - SSA
  - FIG
  - LATAM
- Emea
  Bonds
  / Emea
- Asia
  Bonds
  / Asia
- Emerging Markets
  Bonds
  / Emerging Markets
Securitisation
Securitisation
ESG
ESG
Equities
Equities
Loans
Loans
Rates
Rates
Economics
Economics
FX
FX
Data
Data
New Issues
New Issues

Home
People & Markets
People & Markets
Bonds
Bonds
- Global
  Bonds
  / Global
- Americas
  Bonds
  / Americas
  - Corporate
    Bonds
    / Americas
    / Corporate
    Investment Grade
    High Yield
  - SSA
  - FIG
  - LATAM
- Emea
  Bonds
  / Emea
- Asia
  Bonds
  / Asia
- Emerging Markets
  Bonds
  / Emerging Markets
Securitisation
Securitisation
ESG
ESG
Equities
Equities
Loans
Loans
Rates
Rates
Economics
Economics
FX
FX
Data
Data
New Issues
New Issues

IFR Extra
IFR Extra
IFR Featured
IFR Featured
SIGN IN
REQUEST A TRIAL
My IFR
My Account
My Account
Log Out

There are new features available.
View now.

Search

Type a keyword to start your search

Search for ''

news

Go to news search

Deals

Go to Deals search

Issuers

Go to Issuers search

Destinations

Go to Destinations search

Create an alert Bookmark this page

Drug developer funds to 2017

IFR 2118 30 January to 5 February 2016

4 min read

Robert Sherwood

You need to be a subscriber to view this content.

Sign in Request a trial

Top Stories from the Magazine

Investors queue up for CVC's €1.25bn-plus IPO

EMEA

IFR 2530 - 20 Apr - 26 Apr

Goldman leads investment banking revival

Americas

IFR 2530 - 20 Apr - 26 Apr

Investors cast doubt on putative Thames Water bond plans

EMEA

IFR 2530 - 20 Apr - 26 Apr

Kemble creditors unite

EMEA

IFR 2530 - 20 Apr - 26 Apr

Rubrik brings 2024's first software IPO

Americas

IFR 2530 - 20 Apr - 26 Apr

Tea chain IPO bags rich pricing

Asia

IFR 2530 - 20 Apr - 26 Apr

Debt-for-nature players push to standardise

EMEA, Emerging Markets

IFR 2530 - 20 Apr - 26 Apr

Planisware pops on IPO return

EMEA

IFR 2530 - 20 Apr - 26 Apr

Robert Venes, Tom Hill

US corporates shun ESG-linked loans

Americas

IFR 2530 - 20 Apr - 26 Apr

IFC to kick-start MDB securitisations

EMEA, Emerging Markets

IFR 2530 - 20 Apr - 26 Apr

Sri Lanka investors propose anti-corruption bond

BON RATE P&M ESG

Global

IFR 2530 - 20 Apr - 26 Apr

Christopher Spink

Transition overcomes ESG taboo in US

Americas

IFR 2530 - 20 Apr - 26 Apr

'Last call' for tight CLOs as managers dash to print

EMEA

IFR 2530 - 20 Apr - 26 Apr

Richard Metcalf

Japan's loan market facing reset

Asia

IFR 2530 - 20 Apr - 26 Apr

Rubrik IPO expected to price top of range

Americas

About Us Contact Us Advertise Events IFR Help Special Reports Roundtables IFR Awards IFR Asia Awards

My IFR Alerts Bookmarks Saved Searches Account Settings

Privacy & Cookies

Copyright & Disclaimer

Browser Requirements

© 2024 London Stock Exchange Group. All rights reserved.

Copyright & Disclaimer

© 2024 London Stock Exchange Group. All rights reserved.

Our Privacy Statement & Cookie Policy

All websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

Privacy Statement Cookie Policy